Literature DB >> 18550735

Prevalence of toxic shock syndrome toxin 1 (TSST-1)-producing strains of Staphylococcus aureus and antibody to TSST-1 among healthy Japanese women.

Jeffrey Parsonnet1, Richard V Goering, Melanie A Hansmann, Michaelle B Jones, Kumiko Ohtagaki, Catherine C Davis, Kyoichi Totsuka.   

Abstract

Many cases of neonatal toxic shock syndrome (TSS)-like exanthematous disease but few cases of menstrual TSS (mTSS) have been reported in Japan. We determined the prevalence of mucosal colonization with Staphylococcus aureus and of positive antibodies to TSS toxin 1 (TSST-1) among 209 healthy Japanese women in Tokyo. S. aureus isolates from mucosal sites were characterized with respect to TSST-1 production and resistance genotype. Antibody titers were determined for test subjects and for 133 Japanese and 137 Caucasian control women living in the United States. S. aureus was isolated from at least one site in 108 of 209 women (52%) in Tokyo. Of the 159 S. aureus isolates recovered, 14 (9%) were TSST-1 positive (12 unique strains). Twelve of 209 women (6%) were colonized with a TSST-1-producing strain; two (<1%) had vaginal colonization. Only 2 of 12 unique toxigenic strains (14%) were methicillin resistant. Of the 12 TSST-1-positive strains isolated, 6 (50%) were pulsed-field gel electrophoresis type USA200, multilocus sequence type clonal complex 30. Fewer Japanese women in Tokyo (47%) than Caucasian and Japanese women in the United States (89% and 75%, respectively) had TSST-1 antibodies. The prevalences of colonization with TSST-1-producing S. aureus were comparable in Japan and the United States, despite low seropositivity to TSST-1 in Japan. Environmental factors appear to be important in promoting the development of anti-TSST-1 antibodies, as there was a significant difference in titers between Japanese women living in Tokyo and those living in the United States. Most colonizing TSST-1-producing S. aureus strains in Japan were genotypically similar to mTSS strains found in the United States.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18550735      PMCID: PMC2519460          DOI: 10.1128/JCM.00228-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  41 in total

1.  Prospective surveillance of community-onset and healthcare-associated methicillin-resistant Staphylococcus aureus isolated from a university-affiliated hospital in Japan.

Authors:  Chuncheng Piao; Toshiko Karasawa; Kyoichi Totsuka; Takehiko Uchiyama; Ken Kikuchi
Journal:  Microbiol Immunol       Date:  2005       Impact factor: 1.955

2.  Dissemination of methicillin-resistant staphylococci among healthy Japanese children.

Authors:  Ken Hisata; Kyoko Kuwahara-Arai; Munetaka Yamanoto; Teruyo Ito; Yasuo Nakatomi; Longzhu Cui; Tadashi Baba; Masahiko Terasawa; Chie Sotozono; Shigeru Kinoshita; Yuichiro Yamashiro; Keiichi Hiramatsu
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

3.  Prevalence of serum antibodies to toxic-shock-syndrome-toxin-1 and to staphylococcal enterotoxins A, B and C in West-Germany.

Authors:  E Schröder; G Kunstmann; H Hasbach; G Pulverer
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1988-11

4.  Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women.

Authors:  Jeffrey Parsonnet; Melanie A Hansmann; Mary L Delaney; Paul A Modern; Andrea M Dubois; Wendy Wieland-Alter; Kimberly W Wissemann; John E Wild; Michaelle B Jones; Jon L Seymour; Andrew B Onderdonk
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  [A new exanthematous disease in newborn infants caused by exotoxins producing Staphylococcus aureus; exotoxins production of the isolates and serum levels of antitoxin antibody in the patients and umbilical cord blood].

Authors:  T Okada; S Furukawa; K Miwa; R Sakai; J Sugiyama
Journal:  Kansenshogaku Zasshi       Date:  1999-09

6.  Postoperative toxic shock syndrome caused by a highly virulent methicillin-resistant Staphylococcus aureus strain.

Authors:  L Cui; H Kasegawa; Y Murakami; H Hanaki; K Hiramatsu
Journal:  Scand J Infect Dis       Date:  1999

7.  Use of multiplex PCR to detect classical and newly described pyrogenic toxin genes in staphylococcal isolates.

Authors:  S R Monday; G A Bohach
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

8.  Active surveillance for toxic shock syndrome in the United States, 1986.

Authors:  S Gaventa; A L Reingold; A W Hightower; C V Broome; B Schwartz; C Hoppe; J Harwell; L K Lefkowitz; S Makintubee; D R Cundiff
Journal:  Rev Infect Dis       Date:  1989 Jan-Feb

9.  Intranasal immunization of mutant toxic shock syndrome toxin 1 elicits systemic and mucosal immune response against Staphylococcus aureus infection.

Authors:  Kouji Narita; Dong-Liang Hu; Takao Tsuji; Akio Nakane
Journal:  FEMS Immunol Med Microbiol       Date:  2008-02-27

10.  Specific tests for nasal permeability.

Authors:  Renato Roithmann
Journal:  Braz J Otorhinolaryngol       Date:  2007 Jan-Feb
View more
  18 in total

1.  Inhibition of Staphylococcus aureus by lysostaphin-expressing Lactobacillus plantarum WCFS1 in a modified genital tract secretion medium.

Authors:  Huanli Liu; Yuan Gao; Li-Rong Yu; Richard C Jones; Christopher A Elkins; Mark E Hart
Journal:  Appl Environ Microbiol       Date:  2011-10-07       Impact factor: 4.792

2.  Characterization of three Staphylococcus aureus isolates from a 17-year-old female who died of tampon-related toxic shock syndrome.

Authors:  Yi-Wei Tang; Eric Himmelfarb; Marcia Wills; Charles W Stratton
Journal:  J Clin Microbiol       Date:  2010-03-29       Impact factor: 5.948

3.  Genotyping of methicillin-resistant Staphylococcus aureus from sepsis patients in Pakistan and detection of antibodies against staphylococcal virulence factors.

Authors:  Stefan Monecke; Muhammad Ali Syed; Mushtaq Ahmad Khan; Shehzad Ahmed; Sadia Tabassum; Darius Gawlik; Elke Müller; Annett Reissig; Sascha D Braun; Ralf Ehricht
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-03       Impact factor: 3.267

4.  Staphylococcal toxic shock syndrome: mechanisms and management.

Authors:  Jonathan A Silversides; Emma Lappin; Andrew J Ferguson
Journal:  Curr Infect Dis Rep       Date:  2010-09       Impact factor: 3.725

5.  Superantigens in Staphylococcus aureus isolated from prosthetic joint infection.

Authors:  Choon K Kim; Melissa J Karau; Kerryl E Greenwood-Quaintance; Ashenafi Y Tilahun; Chella S David; Jayawant N Mandrekar; Robin Patel; Govindarajan Rajagopalan
Journal:  Diagn Microbiol Infect Dis       Date:  2014-11-24       Impact factor: 2.803

Review 6.  Device-Associated Menstrual Toxic Shock Syndrome.

Authors:  Patrick M Schlievert; Catherine C Davis
Journal:  Clin Microbiol Rev       Date:  2020-05-27       Impact factor: 26.132

7.  Population structure of Staphylococcus aureus strains isolated from intensive care unit patients in the netherlands over an 11-year period (1996 to 2006).

Authors:  M I A Rijnders; R H Deurenberg; M L L Boumans; J A A Hoogkamp-Korstanje; P S Beisser; E E Stobberingh
Journal:  J Clin Microbiol       Date:  2009-10-07       Impact factor: 5.948

8.  Molecular epidemiology of Staphylococcus aureus in asymptomatic carriers.

Authors:  S Monecke; C Luedicke; P Slickers; R Ehricht
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-05-12       Impact factor: 3.267

9.  The vaginal bacterial communities of Japanese women resemble those of women in other racial groups.

Authors:  Xia Zhou; Melanie A Hansmann; Catherine C Davis; Haruo Suzuki; Celeste J Brown; Ursel Schütte; Jacob D Pierson; Larry J Forney
Journal:  FEMS Immunol Med Microbiol       Date:  2009-10-03

10.  Prevalence of Staphylococcus aureus strains in an Australian cohort, 1989-2003: evidence for the low prevalence of the toxic shock toxin and Panton-Valentine leukocidin genes.

Authors:  S Schlebusch; J M Schooneveldt; F Huygens; G R Nimmo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-05-24       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.